Heat shock protein-peptide complexes as immunotherapy for human cancer

Molecular Medicine Today

Volumn 4, Issue 11, 1998, Pages 478-484

  Przepiorka, Donna ^a   Srivastava, Pramod K ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN; PEPTIDE; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIGEN PRESENTATION; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; COMPLEX FORMATION; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REVIEW; T LYMPHOCYTE; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; AUTOIMMUNITY; CANCER VACCINES; CHAPERONINS; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PEPTIDES;

EID: 0031790229     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01345-8     Document Type: Review

References (44)

1. Maloney D.G.et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:1997;2188-2195.
2. Oettgen, H.F. and Old, L.J. (1995) The history of cancer immunotherapy, in Biologic Therapy of Cancer (DeVita, V.T., Hellman, S. and Rosenberg, S.A.), pp. 87-119, Lippincott.
3. Weiden P.et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. New Engl. J. Med. 300:1979;1068-1073.
4. Kolb H.J.et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 86:1995;2041-2050.
5. Rosenberg S.A.et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl. J. Med. 316:1987;889-897.
6. Morton D.L. Active immunotherapy against cancer: Present status. Semin. Oncol. 13:1986;180-185.
7. Hoover H.C.et al. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer. 55:1985;1236-1243.
8. Linehan D.C., Goedegebuure P.S., Eberlein T.J. Vaccine therapy for cancer. Ann. Surg. Oncol. 3:1996;219-228.
9. Ritossa F. A new puffing pattern induced by temperature shock and DNP in Drosophila. Experientia. 18:1962;571-573.
10. Srivastava P.K., Das M.R. The serologically unique cell surface antigen of Zajdela ascitic hepatoma is also its tumor-associated transplantation antigen. Int. J. Cancer. 33:1984;417-422.
11. Srivastava P.K., DeLeo A.B., Old L.J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. U. S. A. 83:1986;3407-3411.
12. Li Z., Srivastava P.K. Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J. 12:1993;3143-3151.
13. Csermely P.et al. Autophosphorylation of grp94 (endoplasmin). J. Biol. Chem. 270:1995;6381-6388.
14. Altmeyer A.et al. Tumor-specific cell surface expression of the - KDEL containing endoplasmic reticular heat shock protein gp96. Int. J. Cancer. 69:1996;340-349.
15. Munro S., Pelham H.R. A C-terminal signal prevents secretion of luminal ER proteins. Cell. 48:1987;899-907.
16. Schaiff W.T.et al. HLA-DR associates with specific stress proteins and is retained in the endoplasmic reticulum in invariant chain negative cells. J. Exp. Med. 176:1992;657-666.
17. Melnick J., Dul J.L., Argon Y. Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum. Nature. 370:1994;373-375.
18. Lammert E.et al. The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur. J. Immunol. 27:1997;923-927.
19. Arnold D.et al. Influences of transporter associated with antigen processing (TAP) on the repertoire of peptides associated with the endoplasmic reticulum-resident stress protein gp96. J. Exp. Med. 186:1997;461-466.
20. Nieland T.J.et al. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc. Natl. Acad. Sci. U. S. A. 93:1996;6135-6139.
21. Feige U., Polla B.S. Hsp70 - a multi-gene, multi-structure family with potential clinical applications. Experientia. 50:1994;979-986.
22. Stuart R.A., Cyr D.M., Neupert W. Hsp70 in mitochondrial biogenesis: From chaperoning nascent polypeptide chains to facilitation of protein degradation. Experientia. 50:1994;1002-1011.
23. Fourie A.M., Sambrook J.F., Gething M.J. Common and divergent peptide binding specificities of hsp70 molecular chaperones. J. Biol. Chem. 269:1994;30470-30478.
24. Li Z., Srivastava P.K. A critical contemplation on the role of heat shock proteins in transfer of antigenic peptides during antigen presentation. Behring. Inst. Mitt. 94:1994;37-47.
25. Schirmbeck R., Reimann J. Peptide transporter-independent, stress protein-mediated endosomal processing of endogenous protein antigens for major histocompatibility complex class I presentation. Eur. J. Immunol. 24:1994;1478-1486.
26. Multhoff G.et al. CD3-large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72kD heat shock protein on human sarcoma cells. Blood. 86:1995;1374-1382.
27. Kim H.T.et al. γδ T cell recognition of tumor Ig peptide. J. Immunol. 154:1995;1614-1623.
28. Manara G.C.et al. New insights suggesting a possible role of a heat shock protein 70-kD family-related protein in antigen processing/presentation phenomenon in humans. Blood. 82:1993;2865-2871.
29. Feldweg A.M., Srivastava P.K. Molecular heterogeneity of tumor rejection antigen/heat shock protein gp96. Int. J. Cancer. 63:1995;310-314.
30. Udono H., Srivastava P.K. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178:1993;1391-1396.
31. Udono H., Srivastava P.K. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 152:1994;5398-5403.
32. Blachere N.E.et al. Heat shock protein vaccines against cancer. J. Immunother. 14:1993;352-356.
33. Udono H., Levey D.L., Srivastava P.K. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 91:1994;3077-3081.
34. Tiwari R.K.et al. Cancer derived purified heat shock protein, gp96, elicits protective immunity in a rat prostate cancer model. Proc. Annu. Meet. Am. Assoc. Cancer Res. 37:1996;475.
35. Tamura Y.et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 278:1997;117-120.
36. Staveley-O'Carroll K.et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. U. S. A. 95:1998;1178-1183.
37. Blachere N.E.et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186:1997;1315-1322.
38. Chavany C.et al. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J. Biol. Chem. 271:1996;4974-4977.
39. Iwaya K.et al. Natural state of mutant p53 protein and heat shock protein 70 in breast cancer tissue. Lab. Invest. 72:1995;707-714.
40. Suto R., Srivastava P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 269:1995;1585-1588.
41. Srivastava P.K.et al. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics. 39:1994;93-98.
42. Arnold D.et al. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182:1995;885-889.
43. Rosenberg S.A., White D.E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. 19:1996;81-84.
44. Cohen, I.R. (1996) Heat shock protein 60 and the regulation of autoimmunity, in Stress Proteins in Medicine (van Eden, W. and Young, D.B., eds), pp. 93-102, Marcel Dekker Inc.